| This is an Open Access article distributed
under the terms of the Creative Commons Attribution License
(https://creativecommons.org/licenses/by-nc/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Blinatumomab is an anti-CD19 immunotherapy approved for
relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) with
significantly increased survival rate. While blinatumomab showed lower
rates of infection, neutropenia and mucosal barrier injury versus
chemotherapy, its infection risks are not well described.
Patients and Methods
|Table 1. Patient Characteristics.|
|Table 2. Infectious complications.|
|Table 3. Factors associated with nodular, possible mold pneumonia and bacteremia.|